<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709992</url>
  </required_header>
  <id_info>
    <org_study_id>Trospium vs Tamsulosin</org_study_id>
    <nct_id>NCT03709992</nct_id>
  </id_info>
  <brief_title>Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:</brief_title>
  <official_title>Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amiri Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to compare the efficacy and safety of Trospium chloride versus&#xD;
      Tamsulosin for treatment of ureteral stent related symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomized to one of the two treatment groups. Group 1 patients&#xD;
      will receive 30 mg of Trospium chloride tablet twice daily, while group 2 patients will&#xD;
      receive 0.4 mg of Tamsulosin tablet once daily, until the stent is removed. Ureteral Stent&#xD;
      Symptoms Questionnaire (USSQ) will be used to evaluate the symptoms of the patients with DJ&#xD;
      stent after 2 weeks of inserting the stent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ureteral Stent Symptoms Questionnaire (USSQ) score</measure>
    <time_frame>14 days</time_frame>
    <description>Quantitative assessment of quality of life score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>Assessment of side effects of the drug used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ureter Stone</condition>
  <condition>Quality of Life</condition>
  <condition>Ureter Obstruction</condition>
  <arm_group>
    <arm_group_label>Trospium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 30 mg of Trospium chloride tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 0.4 mg of Tamsulosin tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trospium Chloride</intervention_name>
    <description>30 mg of Trospium chloride tablet twice daily</description>
    <arm_group_label>Trospium</arm_group_label>
    <other_name>Spasmix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>0.4 mg of Tamsulosin tablet once daily</description>
    <arm_group_label>Tamsulosin</arm_group_label>
    <other_name>Omnic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with double &quot;J&quot; (DJ) stent after ureteroscopy or for drainage of obstructed&#xD;
             kidney&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with hypersensitivity to either Trospium chloride or Tamsulosin&#xD;
&#xD;
          2. Patients with complications after DJ insertion (such as fever, hematuria, perforation,&#xD;
             stent migration).&#xD;
&#xD;
          3. Patients receiving alpha blockers or anticholinergic medications for any other reason.&#xD;
&#xD;
          4. Patients with history of orthostatic hypotension.&#xD;
&#xD;
          5. Pregnant or breastfeeding females.&#xD;
&#xD;
          6. Patients with hepatic impairment (Child-Pugh score &gt;9).&#xD;
&#xD;
          7. Patients with severe renal impairment with creatinine clearance of less than 15&#xD;
             mL/min.&#xD;
&#xD;
          8. Patients with narrow-angle glaucoma.&#xD;
&#xD;
          9. Patients with history of urinary retention or gastric retention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullatif AL-Terki, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Amiri Hospital - Kuwait</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed R Elnahas, MD</last_name>
    <phone>0096555754386</phone>
    <email>ar_el_nahas@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Majd M Alkabbani, MD</last_name>
    <phone>0096596987198</phone>
    <email>majd.qabbani@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ahmed R EL-Nahas</name>
      <address>
        <city>Mansoura</city>
        <state>Kuwait</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed R EL-Nahas, MD</last_name>
      <phone>+96555754386</phone>
      <phone_ext>0096596987198</phone_ext>
      <email>ar_el_nahas@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Majd M Alkabbani, MD</last_name>
      <phone>0096596987198</phone>
      <phone_ext>0096596987198</phone_ext>
      <email>majd.qabbani@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <removed_countries>
    <country>Kuwait</country>
  </removed_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>December 25, 2020</last_update_submitted>
  <last_update_submitted_qc>December 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed R. EL-Nahas</investigator_full_name>
    <investigator_title>Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>ureteral stent</keyword>
  <keyword>USSQ</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Trospium Chloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ureteral Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Trospium chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

